Literature DB >> 6754875

Rejection encephalopathy. An acute neurological syndrome complicating renal transplantation.

M L Gross, P Sweny, R M Pearson, J Kennedy, O N Fernando, J F Moorhead.   

Abstract

Fifteen episodes of encephalopathy have been studied in 13 renal transplant recipients. All episodes of encephalopathy occurred during an acute rejection crisis. Clinical and biochemical features were recorded during rejection crises associated with encephalopathy and in an equal number of uncomplicated rejection episodes in the same patients. Encephalopathy was related to the severity of the rejection crisis and not to other features such as blood pressure, fever, steroid therapy or plasma electrolytes. The definition of the syndrome of rejection encephalopathy and its relation to the severity of the rejection has important therapeutic implications. Steroid therapy should not be withdrawn or reduced because of acute neurological features. Control of hypertension, fluid overload and electrolyte imbalance, in addition to treatment of the rejection episode, are necessary to reverse the encephalopathy. The prognosis of this syndrome is excellent with no long-term sequelae.

Entities:  

Mesh:

Year:  1982        PMID: 6754875     DOI: 10.1016/0022-510x(82)90058-2

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

Review 1.  Central nervous system infection during immunosuppression.

Authors:  Joseph R Zunt
Journal:  Neurol Clin       Date:  2002-02       Impact factor: 3.806

2.  [EEG findings in patients with a kidney transplant].

Authors:  K L Wendland; M Butschkau; A Gundel
Journal:  Klin Wochenschr       Date:  1988-11-15

3.  Convulsions associated with cyclosporin A in renal transplant recipients.

Authors:  M L Gross; R M Pearson; P Sweny; J F Moorhead
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-16

Review 4.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.